OrbiMed’s Neuronetics STIM Stock Holding History

OrbiMed’s Portfolio STIM Stock Details STIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-150,000	Closed	-$4.81M	–	149
2018 Q3	$4.81M	Hold	150,000	–	–	0.06%	129
2018 Q2	$3.99M	Buy	+150,000	New	+$4.08M	0.05%	131

Other funds holding STIM

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

OrbiMed's STIM Position: Q4 2018 in Review

OrbiMed sold out of Neuronetics (STIM) in Q4 2018, closing a stake of 150,000 shares — an estimated $4.81M sold.

OrbiMed first reported a position in STIM in Q2 2018 and held it in 2 quarters. The position peaked at $4.81M in Q3 2018. 62 funds tracked by Wall St. Rank hold STIM as of Q4 2018.

OrbiMed reported no remaining Neuronetics position as of Q4 2018 after selling out during the quarter.
OrbiMed sold 150,000 Neuronetics shares in Q4 2018, an estimated $4.81M.
OrbiMed first reported a position in Neuronetics in Q2 2018 and held it in 2 quarters.
OrbiMed's Neuronetics position peaked at $4.81M in Q3 2018.
62 funds tracked by Wall St. Rank held Neuronetics as of Q4 2018.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.